PRISTIQ

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Ecuador, Hong Kong SAR China, Mexico, Singapore, Spain.

Active ingredients

The drug PRISTIQ contains one active pharmaceutical ingredient (API):

1	Desvenlafaxine UNII ZB22ENF0XR - DESVENLAFAXINE SUCCINATE
	Desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI), indicated for the treatment of major depressive disorder [MDD]. The clinical efficacy of desvenlafaxine is thought to be related to the potentiation of these neurotransmitters in the central nervous system.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PRISTIQ Extended-release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AX23	Desvenlafaxine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9366Y, 9367B
BR	Câmara de Regulação do Mercado de Medicamentos	522710305111213, 522710306116219, 522710307112217, 522710308119215, 522710310113210
CA	Health Products and Food Branch	02321092, 02321106
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H7501013, H7511013
ES	Centro de información online de medicamentos de la AEMPS	75560, 75561
HK	Department of Health Drug Office	59472, 59473, 65147
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	016M2009
SG	Health Sciences Authority	13858P, 13859P
US	FDA, National Drug Code	0008-1210, 0008-1211, 0008-1222, 43063-262